Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.
|Original language||English (US)|
|Number of pages||3|
|Journal||Investigational New Drugs|
|State||Published - May 1990|
- small cell lung cancer
ASJC Scopus subject areas
- Pharmacology (medical)